Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade and Bone Formation in Relapsed/Refractory Multiple Myeloma
NCT00128921Phase 2Terminated
- Sponsor
- University of Arkansas
- Start
- Apr 2006
- Primary completion
- Feb 2008
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib in multiple myeloma (MM) (3 arms), sponsored by University of Arkansas. Primary endpoints: Number of Participants With a Positive Response to Bortezomib Measured by the Bone Marker Parathyroid Hormone at 6 months, Number of Participants With a Positive Response to Bortezomib Measured by Bone Markers Like Calcium at 6 months and 3 more. Started Apr 2006; status: terminated.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00128921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00128921.